Thursday 7 May, 2026
Objectives: INVENTS project (https://invents-he.eu/) aims to assess and improve modelling and simulation approaches and their regulatory acceptance to expedite drug…
Read morePoster: Drug/Disease Modelling - Paediatrics
Simulation-based guideline implementation of weight-banded dosing strategies for childhood leprosy
Thursday 7 May, 2026
Introduction Leprosy remains an important cause of morbidity among children in vulnerable settings. Treatment consists of a 6- to 12-month…
Read moreNORMALIZATION TO BODY WEIGHT IN PAEDIATRIC PHARMACOKINETICS: IMPACT ON CLEARANCE SCALING
Thursday 7 May, 2026
Introduction/Objectives: Clearance (CL) is a primary determinant of systemic exposure and plays a central role in dose selection and optimization….
Read morePopulation pharmacokinetic (popPK) analysis of tenofovir alafenamide (TAF) and tenofovir (TFV) in children with HIV-1 ≥1 month of age
Thursday 7 May, 2026
Introduction/Objectives: Tenofovir alafenamide (TAF) is a second generation oral prodrug of tenofovir (TFV), a nucleotide analog that inhibits HIV type…
Read moreModel-informed extrapolation of pyrazinamide brain exposure in children with tuberculous meningitis
Thursday 7 May, 2026
Introduction: Tuberculous meningitis (TBM) manifests as the most devastating form of paediatric tuberculosis, causing high mortality rates and neurological sequelae…
Read morePopulation pharmacokinetic analysis of etoposide and model-based dosing evaluation in pediatric oncology
Thursday 7 May, 2026
Introduction Etoposide is an antineoplastic podophyllotoxin derivative that inhibits topoisomerase II, resulting in irreversible DNA strand breaks and cell apoptosis…
Read moreCAN AN EXISTING PEDIATRIC PHYSIOLOGICALLY-BASED PREDICTED PHARMACOKINETIC (PBPK) MODEL FOR CEFEPIME BE USED FOR EXTRAPOLATION TO YOUNGER INFANTS?
Thursday 7 May, 2026
Objectives: Physiologically based pharmacokinetic (PBPK) modelling is a tool increasingly used to support pediatric dosing decisions during drug development. In…
Read morePopulation pharmacokinetics of aprocitentan and dose rationale for paediatric patients aged from 2 to less than 18 years affected by pulmonary arterial hypertension.
Thursday 7 May, 2026
Objectives: Pulmonary arterial hypertension (PAH) is defined by elevated pulmonary vascular resistance, leading to right heart failure and ultimately death…
Read morePopulation pharmacokinetics and exposure-response analysis of tideglusib in children and adolescents with congenital myotonic dystrophy type 1
Thursday 7 May, 2026
Objectives. Tideglusib is an orally administered, brain-penetrant, irreversible inhibitor of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase involved in multiple…
Read moreEVALUATION OF MODEL SELECTION AND AVERAGING ALGORITHMS FOR MODEL-INFORMED PRECISION DOSING OF GENTAMICIN IN NEONATES
Thursday 7 May, 2026
Objectives: Gentamicin is widely used to treat bacterial infections, including those in neonatal patients. Elevated trough concentrations frequently lead to…
Read more